Chemotherapy for Brain Metastases: Breast, Gynecologic and Non-Melanoma Skin Malignancies
Greater than one-half of all intracranial tumors in adults represent metastases from disseminated systemic malignancies. Abundant class I evidence has been accumulated for the past two decades that demonstrates improved survival and quality of life with surgical resection or SRS for appropriate patients. In some tumor types, WBRT can effectively treat, prevent and/or delay recurrences and improve survival as well. However, several factors may preclude either surgery or radiation therapy (e.g., number of metastases, co-existing medical or neurological conditions) and in such patients the mainstay of treatment is chemotherapy or other biologic targeted therapy.
KeywordsBrain Metastasis Endometrial Cancer Clin Oncol Epithelial Ovarian Cancer Germ Cell Tumor
Unable to display preview. Download preview PDF.
- 9.Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605–13.CrossRefPubMedGoogle Scholar
- 20.Burris HA, 3rd, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23(23):5305–13.CrossRefPubMedGoogle Scholar
- 22.Geyer C, Cameron D, Lindquist D, et al. A phase III, randomized open-label, Internationsl study comparing lapatinib and capecitabine versus capecitabine in women with refractory advanced or metastatic breast cancer (abstract). Data presented at the annual meeting of the American Society of Clinical Oncology, 2006. 2006.Google Scholar